echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > PLOS MED: Use medicine with caution!

    PLOS MED: Use medicine with caution!

    • Last Update: 2021-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hypnotics are one of the most commonly prescribed drugs used by the elderly
    .
    In the United States, the three most common prescription drugs for insomnia are benzodiazepines, class Z drugs, and low-dose trazodone


    .


    In the United States, the three most common prescription drugs for insomnia are benzodiazepines, class Z drugs, and low-dose trazodone


    Trazodone is an antidepressant without GABA activity.


    Although the main problems with benzodiazepines and class Z drugs are dependence and the risk of injury, these drugs also have potentially fatal respiratory effects


    .


    Benzodiazepines inhibit breathing and therefore exacerbate sleep-disordered breathing, which in turn can cause life-threatening arrhythmias


    The retrospective cohort study included 400,924 medical insurance beneficiaries over 65 years of age who had no evidence of serious illness or substance use disorder.
    From January 2014 to September 2015, they began to study sleep aid treatment
    .
    The study endpoints are out-of-hospital (primary) and total mortality


    .


    diagnosis

    Test procedure

    The results showed that there are currently 32,388 person-years of patients without concurrent opioid use, 260 (8.
    0/1,000 person-years) out-of-hospital and 418 (12.
    9/1,000) total deaths of benzodiazepines; 26,497 person-years, 150 (5 7/1,000), 227 deaths out of hospital (8.
    6/1,000); and 16,177 person-years, 156 (9.
    6/1,000) deaths out of hospital, and 256 (15.
    8/1,000) total deaths of trazolone
    .
    In general, there was no difference in the out-of-hospital and total mortality of benzodiazepines (HRs=0.


    99; 95%CI: 81-1.


    There was no difference in the out-of-hospital and total mortality of benzodiazepines (HRs=0.


    Adjusted HR for out-of-hospital and total mortality of benzodiazepines and class Z drugs and trazodone based on concurrent opioid use

    Patients who use opioids at the same time currently use 4278 person-years, 90 people (21.


    0/1,000) died out of hospital, 127 people (29.


    Compared with trazodone, the out-of-hospital and total mortality of benzodiazepines increased by 202% and 121%, respectively (HRs=3.


    In summary, if opioids are used at the same time, the use of benzodiazepines and class Z drugs in the elderly is associated with an increase in out-of-hospital and overall mortality


    references:

    Mortality and concurrent use of opioids and hypnotics in older patients: A retrospective cohort study.
    https://doi.
    org/10.
    1371/journal.
    pmed.
    1003709

    Mortality and concurrent use of opioids and hypnotics in older patients: A retrospective cohort study.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.